Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02203903
Title Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE)
Acronym RESOLVE
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Catherine Bollard
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries USA


No variant requirements are available.